SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait!

Shayan Rahmani¹, ², Nima Rezaei², ³, ⁴
¹Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ²Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; ³Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; ⁴Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract. On November 26th, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), B.1.1.529, was designated by the World Health Organization (WHO) as a variant of concern (VOC) and named Omicron. The news raised an international alarm about a new wave of coronavirus disease 2019 (Covid-19) outbreak, since Omicron has a large group of mutations, which may affect the way it spread, cause disease, and escape from the immunity. Therefore, it is essential to take a closer look at how it has emerged, how it may sustain the pandemic, and how we can act correspondingly, both nationally and internationally, to help controlling the spread of the disease. (www.actabiomedica.it)

Key words: SARS-CoV-2, coronavirus disease, Covid-19, omicron variant, b.1.1.529, Variant of concern, pandemic, africa, world health organization, mutation, emergence, transmissibility, immune escape, infection, vaccine resistance, healthcare system, hospitalization, preventive strategies, health recommendations, international collaboration

Introduction

About two years after the first cases of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have identified in Wuhan, China; on November 26th 2021, a new SARS-CoV-2 variant of concern (VOC) was designated by the World Health Organization (WHO) and named Omicron. The news raised an international alarm about a new wave of coronavirus disease 2019 (Covid-19) outbreak, since Omicron has a large group of mutations, which may affect the way it behaves (3). Besides, the fact that it can potentially cause infection in people who have already been infected or fully vaccinated, suggests that it may have been evolved to escape more easily from the vaccine-induced or pre-existing immunity (4, 5). Therefore, it is essential to take a closer look at how it has emerged, how it may sustain the pandemic, and how we can act correspondingly, both nationally and internationally, to help controlling the spread of the disease.

Importance

The first confirmed B.1.1.529 sample was collected in Botswana on November 9th, about 2 weeks earlier than its initial detection on South Africa and
the official WHO statement (1). After first cases in Africa, other parts of the world announced their first Omicron cases through sharing their sample collection. Some cases were directly travelled from southern African countries, while others had no history of crossing their borders, yet tested positive for Omicron variant. It means that despite official data, the new variant had been circulated in nations around the world, and now, 179 countries are reported Omicron from their PCR sampling (2).

Based on the latest WHO statement on enhancing readiness for Omicron, the overall risk associated with Omicron variant remains very high (6). Initial data suggest there are about 50 mutations on the genome of the virus, of which 32 are on the spike and 15 belongs to the receptor-binding domain (RBD) (4, 7), which has been targeted previously by the most vaccines (8). There are also three mutations on the furin cleavage site (FCS), which is associated with increased viral infectivity (9, 10). This huge amount of mutations raised an alarm for the global communities as it can potentially increase transmissibility, vaccine resistance, and virulence of the virus. As a comparison, the number of mutations on the genomic sequence of the Delta variant was 9, 2, and 1 for the spike, RBD, and FCS, respectively (7, 11). Some researchers also proposed that the Omicron might have a higher affinity to the human ACE-2 receptor than the Delta variants (12, 13). Despite preliminary data suggested higher transmissibility and reduced antibody neutralization for Omicron variant (14, 15), further investigations proposed that severe Covid-19 outcomes and hospitalization followed by Omicron is meaningfully lower than other variants, including Delta (16, 17). However, the rate of hospitalizations remain high mainly due to extreme transmissibility of the lineage and novel structure of the spike protein through extensive mutations in the RBD region (18-20).

Whether the Omicron variant has originated in Africa or not, the first cases are always the key to understanding the spreading pattern of the disease. Since the rate of HIV infection is relatively high in African nations (21), it is hypothesized that these large mutations could occur during a chronic Covid-19 infection within an immune-compromised population, which probably has a lower vaccination rate and weak healthcare infrastructures. This could lead to remaining a group of viruses in such hidden population, and evolved new mutations gathered in one single burst (22, 23). In another theory, the virus could have been hidden in rodents or other animal reservoirs, evolved for a while, and then returned to the human population with a relatively different genomic appearance (24). Taken together, what makes Omicron a new global concern is the rapid spreading of cases across the world, even in populations with higher vaccination coverage, which appears to be out-competing previous variants much faster than before (6, 25, 26).

To the best of our knowledge, widely used PRC tests are detecting Omicron as effective as previous variants. Based on the WHO statement, IL-6 receptor blockers and corticosteroids are still effective therapeutic choices for severe Covid-19 infection, while monoclonal antibodies such as sotrovimab (VIR-7831) are also suggested to preserve immunity against Omicron (3, 27). Recent investigations on vaccines effectiveness provided essential clues on how Omicron can affect vaccine-induced immunity. Several studies reported that mRNA vaccines can offer a similar degree of viral protection against Omicron compared to the previous variants; however, vaccine-induced immunity against symptomatic disease and severe infection will be wane within several weeks (28, 29). The result of other studies also proposed that primary vaccination with two doses of anti-Covid vaccines provide limited protection against Covid-19 caused by the Omicron. However, a booster dose can substantially increase vaccine-induced immunity, even in patients suffered from cancer (30, 31). Although the effectiveness of anti-Covid vaccines against transmission of the Omicron wave is limited, vaccines remained crucial to decrease severe disease, hospitalization, and death, caused by different SARS-CoV-2 variants. (32, 33).

**Recommendations**

With any new SARS-CoV-2 variant, there is a possibility of a surge in new cases and hospital admissions. Therefore, following the recommendations is the key to control the outbreak and further outcomes.
General Recommendations

The best action people can take to lessen the spread of the virus is simple: To not get sick and not to make others sick. To this purpose, following preventive strategies such as wearing a well-fitting mask, washing the hands regularly, appropriate social distancing, avoiding crowded or poorly ventilated places, opening windows and doors to improve ventilation, covering sneezes and coughs with elbow or tissue, and daily cleaning surfaces are crucial (3, 34). Also, regular Covid-19 testing, daily health monitoring, postpone traveling to high community transmissible areas, and more importantly, getting fully vaccinated, along with booster dose are among the most effective ways to control the disease (35, 36). Based on previous studies, there are other ways to help foster the immune system against severe Covid-19 infection. Physical activity and exercise (37, 38), good nutrition (39), diminishing smoking and alcohol (40, 41), listening to the music and enriching the environment (42), especially when you feel isolated, and also, keep up with regular treatments for underlying diseases, such as diabetes and cardiovascular diseases (43, 44) are among the most effective ways.

National Recommendations

After 4 months of its designation, many countries are facilitating restrictive measures against the widespread diffusion of the Omicron, in the assumption of mild symptom of the disease in the majority of vaccinated or pre-infected people. However, due to higher transmissibility, the rate of hospitalization remained high. This can put further pressure on the hospitals and healthcare providers, while putting them at a higher risk of reinfection and vaccines breakthrough infection, caused by Omicron (45-47). Therefore, by setting accurate healthcare policies and prevention strategies, national authorities can also play a critical role in controlling the disease. A travel ban for highly infected countries, restricting international flights, and quarantining passengers even if they are fully vaccinated, could be a great help. However, timing, quality, and conditionality of testing and quarantine requirements should be concordant between nations and countries to prevent logistical difficulties and charging travelers with higher costs (48). Based on research, working from home and having fewer occupational workplaces could also make a huge difference in the rate of infection with Covid-19 (49, 50). Therefore, providing employers and companies with remote work facilities can be helpful. Regular testing and speeding up vaccination rate are also promising ways to protect the society against the possible wave of Omicron infection (36).

International Collaboration

With every mutation, there is a chance for increased transmissibility, immune escape, and severity of the variants. Mutations mostly occur in a population with a lower rate of vaccination since the immune system cannot properly detect or eliminate the virus. As a result, the structure of the SARS-CoV-2 can change more and new spreading waves around the world are more likely to be appear (51). African nations are among the poorest contributors in Covid-19 vaccination (52). Given the highest rate of HIV infection as an immune suppressor disease among South African countries (21), Africa could be a vulnerable place to emerge new strains of the SARS-COV-2 virus. So, it is vital for International communities, vaccine producers, and everyone in power to vaccinate Africa (53), and other less vaccinated nations, which can protect the world against other possible mutations and further variants of concern. If the Omicron is as dangerous as it already appears, setting strict rules on international transportations and local communicatons should be continued. This can prevent damaging already exhausted healthcare systems and provide better healthcare experience for infected people during the pandemic (45, 54). At this time, we need international collaboration more than ever to end the pandemic; after all, the house is still on fire, and we have to save each other or will be burned together.

Conclusion and Future

Omicron variant showed us there are still new aspects of Covid-19 to be concerned about, and after almost two years, an ever-changing outbreak is
still within us with different faces. Living through the lens of previous pandemics has taught us the main contributors in controlling the outbreak are to follow preventive strategies, stay healthy, and get vaccinated as soon as possible. Besides, national and international collaborations remained crucial to diminish the viral load across the borders, while acting borderless is the potential way to end the global pandemic.

There are also some promising points about Omicron. Through relatively new mutations, Omicron may have evolved to a more transmissible strain; however, it is less fetal than previous VOCs, Delta for example. Further studies should be conducted to show how Omicron could shape the future of the pandemic, but until that time, it is essential to stay positive, follow the health recommendations, and remember, “no one is safe until everyone is safe”.

Authors’ Contribution: SR conceptualized the title, collected data, and prepared the first draft of the manuscript. NR critically revised the manuscript, edited and finalized the draft, and supervised the study. All of the authors have read and approved the final draft of the manuscript.

Conflict of Interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.

Acknowledgements: This paper is dedicated to all whose efforts are to make the world a better, safer place, especially amidst the Covid-19 pandemic.

References

1. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. 26 November 2021. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
2. GISAID. Tracking of Variants. https://www.gisaid.org/hcov19-variants/.
3. World Health Organization. Update on Omicron. 28 November 2021. https://www.who.int/news/item/28-11-2021-update-on-omicron.
4. Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021;600(7887):21.
5. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinforcement associated with emergence of the Omicron variant in South Africa. medRxiv. 2021:2021.11.11.21266068.
6. World Health Organization. Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States. 21 January 2022. https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states.
7. Omicron (B.1.1.529) Mutations. Stanford University Coronavirus Antiviral & Resistance Database. https://covdb.stanford.edu/page/mutation-viewer/#omicron.
8. Hossain MK, Hassanzadehnooudsari M, Apostolopoulos V. The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines? Expert Review of Vaccines. 2021;20(6):635-8.
9. Variant: 21K (Omicron). CoVariants. https://covariants.org/variants/21K.Omicron.
10. Johnson BA, Xie X, Bailey AL, Kalveram B, Lokugamage KG, Muruato A, et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021;591(7849):293-9.
11. Delta (B.1.617.2) Mutations. Stanford University Coronavirus Antiviral & Resistance Database. https://covdb.stanford.edu/page/mutation-viewer/#sec_b-1-617-2.
12. Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike protein. bioRxiv. 2021:2021.12.02.470946.
13. Pascarella S, Ciccozzi M, Bianchi M, Benvenuto D, Cauda R, Cassone A. The Electrostatic Potential of the Omicron Variant Spike is Higher than in Delta and Delta-plus Variants: a Hint to Higher Transmissibility? J Med Virol. n/a(n/a).
14. Grabowski F, Kochańczyk M, Lipniacki T. Omicron strain spreads with the doubling time of 3.2—3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant. medRxiv. 2021:2021.12.08.21267494.
15. Wilhelm A, Widera M, Grikščiėtė K, Toptan T, Schenk B, Pallas C, et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. medRxiv. 2021:2021.12.07.21267432.
16. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flassman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. The Lancet.
17. Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. JAMA. 2022.
18. Araf Y, Akter F, Tang Y-d, Patemi R, Parvez MSA, Zheng C, et al. Omicron variant of SARS-CoV-2: Genomics,
transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825-32.
19. Papanikolaou V, Chyrssovergis A, Ragos V, Tsiambas E, Katsinis S, Manoli A, et al. From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. Gene. 2022;814:146134.
20. Ye G, Liu B, Li F. Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain. Nature Communications. 2022;13(1):1214.
21. Jahagirdar D, Walters MK, Novotney A, Brewer ED, Frank TD, Carter A, et al. Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990 & x2013;2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. The Lancet HIV. 2021;8(10):e633-e651.
22. Karim F, Moosa M, Gosnell B, Cele S, Giandhari J, Pillay S, et al. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. medRxiv. 2021:2021.06.03.21258228.
23. Gao S-J, Guo H, Luo G. Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! J Med Virol.n/a(n/a).
24. Kupferschmidt K, Where did ‘weird’ Omicron come from? Science. 1 December 2021. https://www.science.org/content/article/where-did-weird-omicron-come.
25. Daria S, Bhuiyan MA, Islam MR. Detection of highly mutated coronavirus variant Omicron (B.1.1.529) is triggering the alarm for South Asian countries: Associated risk factors and preventive actions. J Med Virol.n/a(n/a).
26. Rahmani S, Rezaei N. SARS-CoV-2 Omicron variant: Why global communities should take it seriously? Immun Inflamm Dis. 2022;e618. doi:10.1002/iid3.618.
27. Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021:2021.03.09.434607.
28. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761.
29. Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, et al. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. medRxiv. 2021:2021.06.03.21258228.
30. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022.
31. Fendler A, Shepherd STC, Au L, Wu M, Harvey R, Schmitt AM, et al. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. The Lancet. 2022;399(10328):905-7.
32. Ying B, Whitener B, VanBlergan LA, Hassan AO, Shrihari S, Liang C-Y, et al. Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. Sci Transl Med.0(0):eabm3302.
33. Krause PR, Fleming TR, Longin IM, Peto R, Briand S, Heymann DL, et al. SARS-CoV-2 Variants and Vaccines. N Engl J Med. 2021;385(2):179-86.
34. Center for Disease Control and Prevention. CDC Statement on B.1.1.529 (Omicron variant). 26 November 2021. https://www.cdc.gov/media/releases/2021/s1126-B11-529-omicron.html.
35. Center for Disease Control and Prevention. Travel. 27 January 2022. https://www.cdc.gov/coronavirus/2019-ncov/travelers/index.html.
36. Center for Disease Control and Prevention. How to Protect Yourself & Others. 25 February 2021. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html.
37. Sallis R, Young DR, Tartof SY, Sallis JF, Sall J, Li Q, et al. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. Br J Sports Med. 2021;55(19):1099-105.
38. da Silveira MP, da Silva Fagundes KK, Bizuti MR, Starck É, Rossi RC, de Resende e Silva DT. Physical exercise as a tool to help the immune system against COVID-19: an integrative review of the current literature. Clin Exp Med. 2021;21(1):15-28.
39. Calder PC. Nutrition and immunity: lessons for COVID-19. Nutr Diabetes. 2021;11(1):19.
40. Patanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. Nicotine & Tobacco Research. 2020;22(9):1653-6.
41. Calina D, Hartung T, Mardare I, Mitroi M, Poulas K, Tsatsakis A, et al. COVID-19 pandemic and alcohol consumption: Impacts and interconnections. Toxicology reports. 2021;8:529-35.
42. Taheri Zadeh Z, Rahmani S, Alidadi F, Joushi S, Esmaeilpour K. Depression, anxiety and other cognitive consequences of social isolation: Drug and non-drug treatments. Int J Clin Pract. 2021;75(12):e14949.
43. Bornstein SR, Rubino F, Khunti K, Magrini G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. The Lancet Diabetes & Endocrinology. 2020;8(6):546-50.
44. Ganatra S, Dani SS, Shah S, Asnani A, Lenihan D, et al. Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. Trends Cardiovasc Med. 2020;30(6):315-25.
45. Rahmani S, Rezaei N. Omicron (B.1.1.529) variant: Development, dissemination, and dominance. J Med Virol. 2022;94(5):1787-8.
46. Temsah M-H, Alenezi S, Alarabi M, Aljamaan F, Alhasan K, Assiri R, et al. Healthcare Workers&rsquo; SARS-CoV-2 Omicron Variant Uncertainty-Related Stress, Resilience, and Coping Strategies during the First Week of the World Health Organization&rsquo;s Alert. Int J Environ Res Public Health. 2022;19(4):1944.
47. Nunes MC, Mbotwe-Sibanda S, Baillie VL, Kwatra G, Aguas R, Madhi SA, et al. SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers. Vaccines. 2022;10(3):459.
48. Schermerhorn J, Case A, Graeden E, Kerr J, Moore M, Robinson-Marshall S, et al. Fifteen days in December: capture and analysis of Omicron-related travel restrictions. BMJ Global Health. 2022;7(3):e008642.
49. Vyas L, Butakhieo N. The impact of working from home during COVID-19 on work and life domains: an exploratory study on Hong Kong. Policy Design and Practice. 2021;4(1):59-76.
50. Mokhtari R, Jahangir MH. The effect of occupant distribution on energy consumption and COVID-19 infection in buildings: A case study of university building. Build Environ. 2021;190:107561.
51. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature Reviews Immunology. 2021;21(10):626-36.
52. Africa Center for Disease Control and Prevention. COVID-19 Vaccination. https://africacdc.org/covid-19-vaccination/.
53. World Health Organization. Joint Statement on Dose Donations of COVID-19 Vaccines to African Countries. 29 November 2021. https://www.who.int/news/item/29-11-2021-joint-statement-on-dose-donations-of-cov-id-19-vaccines-to-african-countries.
54. Mohamed K, Rezaei N, Rodriguez-Román E, Rahmani F, Zhang H, Ivanovska M, et al. International Efforts to Save Healthcare Personnel during COVID-19. Acta Bio-medica: Atenei Parmensis. 2020;91(3):e2020044-e.

Correspondence
Received: 21 December 2021
Accepted: 10 April 2022
Nima Rezaei, MD, PhD
Research Center for Immunodeficiencies
Children’s Medical Center
Dr. Qarib St, Keshavarz Blvd
Tehran 14194, Iran
Phone: +98-21-66929234
Fax: +98-21-66929235
E-mail: rezaei_nima@yahoo.com
ORCiD: https://orcid.org/0000-0002-3836-1827